MarketBeat
08 Oct 2026, 02:02 UTC · 1h ago
Neogen Investor Day Sets Path for Growth, 30% EBITDA Margin by 2031
Impact · against what's priced in
Neogen is establishing a long-term growth and margin trajectory (30% EBITDA by 2031) and reducing supply chain dependence on 3M, which serves as a fresh positive catalyst. For 3M, the loss of Petrifilm supply is a headwind, though small relative to the company's broader structural pivots and litigation hurdles.
- MMM−0.20
Challenges what's priced in
- The price assumes
Sustained Safety and Industrial growth above 3.9%
Neogen is transitioning Petrifilm products to its own manufacturing facility by early 2027, removing a revenue stream from 3M's portfolio and challenging the stability of its industrial growth.
What MMM's price assumes · Aug 26
